ClinicalTrials.gov
ClinicalTrials.gov Menu

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00624936
Recruitment Status : Completed
First Posted : February 28, 2008
Last Update Posted : August 22, 2017
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Celgene Corporation
Information provided by (Responsible Party):
Ohio State University Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 2009
  Actual Study Completion Date : June 2014